Hong Kong Stock Alert: CF PHARMTECH Surges Over 10% in Morning Session as Clinical Approvals for ICF001 Pave the Way for Global Phase I Trials

Stock News

Yesterday

CF PHARMTECH (02652) shares jumped more than 10% early on Thursday before paring gains to trade 8.23% higher at HK$10.39, with turnover reaching HK$28.74 million. The price surge follows the company's announcement that its self-developed long-acting inhaled powder candidate, ICF001, has received implied clinical trial approvals for three additional indications, completing full coverage across four major indications: PAH, PH-ILD, IPF, and PPF, making it the first domestic company to advance this class of long-acting inhaled prodrug into clinical trials in China.

Dr. Liang Wenqing, Chairman and Executive Director, stated that the company will simultaneously advance Phase I clinical studies both domestically and internationally, while actively exploring global partnerships, including overseas co-development and regional licensing opportunities. Notably, at the 2026 Xiamen Science and Technology Innovation Industry and Securities Development Conference held on September 6, the company was honored with the "2026 Technology Innovation Golden Bull Award." This prestigious award, recognized as one of the most credible scientific innovation accolades in China's capital market, underscores the company's commitment to high-end pharmaceutical R&D and its robust global strategy, reinforcing its innovative capabilities in the sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/news/1131192332"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131192332\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131192332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-11 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131192332","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Alert: CF PHARMTECH Surges Over 10% in Morning Session as Clinical Approvals for ICF001 Pave the Way for Global Phase I Trials","media":"Stock News","content":"<p><b>CF PHARMTECH (02652)</b> shares jumped more than 10% early on Thursday before paring gains to trade 8.23% higher at HK$10.39, with turnover reaching HK$28.74 million. The price surge follows the company's announcement that its self-developed long-acting inhaled powder candidate, ICF001, has received implied clinical trial approvals for three additional indications, completing full coverage across four major indications: PAH, PH-ILD, IPF, and PPF, making it the first domestic company to advance this class of long-acting inhaled prodrug into clinical trials in China.<br><br>Dr. Liang Wenqing, Chairman and Executive Director, stated that the company will simultaneously advance Phase I clinical studies both domestically and internationally, while actively exploring global partnerships, including overseas co-development and regional licensing opportunities. Notably, at the 2026 Xiamen Science and Technology Innovation Industry and Securities Development Conference held on September 6, the company was honored with the \"2026 Technology Innovation Golden Bull Award.\" This prestigious award, recognized as one of the most credible scientific innovation accolades in China's capital market, underscores the company's commitment to high-end pharmaceutical R&D and its robust global strategy, reinforcing its innovative capabilities in the sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert: CF PHARMTECH Surges Over 10% in Morning Session as Clinical Approvals for ICF001 Pave the Way for Global Phase I Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert: CF PHARMTECH Surges Over 10% in Morning Session as Clinical Approvals for ICF001 Pave the Way for Global Phase I Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-11 10:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CF PHARMTECH (02652)</b> shares jumped more than 10% early on Thursday before paring gains to trade 8.23% higher at HK$10.39, with turnover reaching HK$28.74 million. The price surge follows the company's announcement that its self-developed long-acting inhaled powder candidate, ICF001, has received implied clinical trial approvals for three additional indications, completing full coverage across four major indications: PAH, PH-ILD, IPF, and PPF, making it the first domestic company to advance this class of long-acting inhaled prodrug into clinical trials in China.<br><br>Dr. Liang Wenqing, Chairman and Executive Director, stated that the company will simultaneously advance Phase I clinical studies both domestically and internationally, while actively exploring global partnerships, including overseas co-development and regional licensing opportunities. Notably, at the 2026 Xiamen Science and Technology Innovation Industry and Securities Development Conference held on September 6, the company was honored with the \"2026 Technology Innovation Golden Bull Award.\" This prestigious award, recognized as one of the most credible scientific innovation accolades in China's capital market, underscores the company's commitment to high-end pharmaceutical R&D and its robust global strategy, reinforcing its innovative capabilities in the sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1131192332","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131192332","pubTimestamp":1789092852,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CF PHARMTECH (02652) shares jumped more than 10% early on Thursday before paring gains to trade 8.23% higher at HK$10.39, with turnover reaching HK$28.74 million. The price surge follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","02652":"长风药业","VXUS":"国际股票ETF-Vanguard","BK1191":"制药","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股"},"translate_title":"港股提醒：ICF001 临床批准为全球 I 期试验铺平道路，CF PHARMTECH 早盘飙升超过 10%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1,"VXUS":1,"KCAI":1},"content_text":"CF PHARMTECH (02652) shares jumped more than 10% early on Thursday before paring gains to trade 8.23% higher at HK$10.39, with turnover reaching HK$28.74 million. The price surge follows the company's announcement that its self-developed long-acting inhaled powder candidate, ICF001, has received implied clinical trial approvals for three additional indications, completing full coverage across four major indications: PAH, PH-ILD, IPF, and PPF, making it the first domestic company to advance this class of long-acting inhaled prodrug into clinical trials in China.Dr. Liang Wenqing, Chairman and Executive Director, stated that the company will simultaneously advance Phase I clinical studies both domestically and internationally, while actively exploring global partnerships, including overseas co-development and regional licensing opportunities. Notably, at the 2026 Xiamen Science and Technology Innovation Industry and Securities Development Conference held on September 6, the company was honored with the \"2026 Technology Innovation Golden Bull Award.\" This prestigious award, recognized as one of the most credible scientific innovation accolades in China's capital market, underscores the company's commitment to high-end pharmaceutical R&D and its robust global strategy, reinforcing its innovative capabilities in the sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}